Bone Therapeutics was granted an additional €2MM (~US $2.15MM) in non-dilutive funding from the Belgian Walloon Region government, bringing the total non-dilutive funding received within 2015 to €5MM.
The new funding will support a 2-year study of ALLOB® allogeneic bone cell therapy, investigating the impact of proteins on bone reconstruction. This data will feed ongoing proof-of-concept studies in the treatment of delayed-union fractures and in spinal fusion.
Bone Therapeutics was granted an additional €2MM (~US $2.15MM) in non-dilutive funding from the Belgian Walloon Region government, bringing the total non-dilutive funding received within 2015 to €5MM.
The new funding will support a 2-year study of ALLOB® allogeneic bone cell therapy, investigating the impact of proteins on...
Bone Therapeutics was granted an additional €2MM (~US $2.15MM) in non-dilutive funding from the Belgian Walloon Region government, bringing the total non-dilutive funding received within 2015 to €5MM.
The new funding will support a 2-year study of ALLOB® allogeneic bone cell therapy, investigating the impact of proteins on bone reconstruction. This data will feed ongoing proof-of-concept studies in the treatment of delayed-union fractures and in spinal fusion.
Copy to clipboard 
